Resources/
Phil Blog
Phil Blog
4 Strategies to Maximize Enrollment in your Patient Services Program
Low enrollment in manufacturer-sponsored patient services programs is rampant, so much so that many industry stakeholders have come to accept this as inevitable. This disappointing trend nearly always holds true if brands employ traditional “call center-based” hubs or specialty pharmacies that lack consumer-friendliness, creating unnecessary friction for patients and HCPs. These “clunky” programs typically result in enrollment rates between 20-30%
Implementing an Effective Bridge Program: Laying the Foundation for Covered Dispenses
A common challenge for specialty and specialty-lite brand commercialization teams is maximizing prescription coverage while minimizing free goods program overutilization. Patient bridge and quickstart programs, which provide temporary access to medications for patients experiencing coverage gaps or delays, are essential for therapy continuity and preventing financial burden on patients. However, these programs can negatively impact the manufacturers’ bottom line if manufacturers don’t implement the appropriate safeguards and requirements
Launching a New Drug in a Category with Generic Alternatives
Getting an innovative prescription drug approved for patient use is a significant milestone – however, it's only the beginning and certainly does not ensure the brand's commercial success. Considering it typically takes ten years and over $2.6 billion for a life sciences manufacturer to move a drug from its initial discovery into the marketplace, commercialization teams must employ effective launch strategies that differentiate their brand to get it into the hands of patients. Launching into a category with generic alternatives presents a unique challenge because payers often limit patients' access to the new entrant through utilization management tools that favor the lower-cost generics
What Makes Phil’s Prior Authorization Process Unique?
The prior authorization process (PA) presents a significant (and growing) roadblock for healthcare providers trying to get a patient started on a prescription therapy they deem best. In general, a PA requirement affects patients' experience with their healthcare. It represents a length of time – and the associated frustration – they must wait to receive their medication or go without the treatment they have been introduced to by their provider and may desperately need
Transforming the Prior Authorization Process: How Feedback Loops can Improve Patient Access to Life Sciences Brands
The use of prior authorization (PA) to control the utilization of prescription drugs, especially specialty medications, is growing, with 79% of medical practices reporting that PA requirements increased between 2021 and 2022. By design, the PA process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. The negative consequences of delaying treatment are well documented, yet more than 8 out of 10 patients still experience delays accessing their medications for reasons such as cost and insurance challenges
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
Create a Path to Commercial Success
Our expert team can build a tailored access program that drives your brand goals.
Our Solutions
About Us
